All In Biotech

Drug Trial Radar · NCT05387707

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 287 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

287

Actual

Start

Aug 16, 2022

Primary completion

Feb 2, 2024

Study completion Feb 2, 2024

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).

Conditions

  • Pruritus
  • Atopic Dermatitis

Interventions

  • difelikefalin 0.25 mgDrug

    Oral difelikefalin 0.25 mg tablets administered twice daily

  • difelikefalin 0.5 mgDrug

    Oral difelikefalin 0.5 mg tablets administered twice daily

  • TCS CreamDrug

    TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed

  • PlaceboDrug

    Oral Placebo tablets administered twice daily

  • Vehicle CreamDrug

    Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving an improvement from baseline ≥4 points with respect to the weekly mean of the daily 24-hour I-NRS score at Week 12Time frame: Week 12

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Scottsdale, Arizona

  • Cara Therapeutics Study Site

    Fort Smith, Arkansas

  • Cara Therapeutics Study Site

    Rogers, Arkansas

  • Cara Therapeutics Study Site

    Fountain Valley, California

  • Cara Therapeutics Study Site

    Lomita, California

  • Cara Therapeutics Study Site

    Los Angeles, California

  • Cara Therapeutics Study Site

    Redwood City, California

  • Cara Therapeutics Study Site

    Sacramento, California

  • Cara Therapeutics Study Site

    San Diego, California

  • Cara Therapeutics Study Site 2

    Santa Monica, California

  • Cara Therapeutics Study Site

    Santa Monica, California

  • Cara Therapeutics Study Site

    Valencia, California

  • Cara Therapeutics Study Site

    Denver, Colorado

  • Cara Therapeutics Study Site

    Brandon, Florida

  • Cara Therapeutics Study Site

    Coral Gables, Florida

  • Cara Therapeutics Study Site

    Delray Beach, Florida

  • Cara Therapeutics Study Site

    Hollywood, Florida

  • Cara Therapeutics Study Site

    North Miami Beach, Florida

  • Cara Therapeutics Study Site

    Orlando, Florida

  • Cara Therapeutics Study Site

    Saint Augustine, Florida

  • Cara Therapeutics Study Site

    St. Petersburg, Florida

  • Cara Therapeutics Study Site

    Sweetwater, Florida

  • Cara Therapeutics Study Site

    Tampa, Florida

  • Cara Therapeutics Study Site

    Marietta, Georgia

  • Cara Therapeutics Study Site

    Indianapolis, Indiana

  • Cara Therapeutics Study Site

    Plainfield, Indiana

  • Cara Therapeutics Study Site

    South Bend, Indiana

  • Cara Therapeutics Study Site

    Overland Park, Kansas

  • Cara Therapeutics Study Site

    Louisville, Kentucky

  • Cara Therapeutics Study Site

    Baton Rouge, Louisiana

  • Cara Therapeutics Study Site

    Houma, Louisiana

  • Cara Therapeutics Study Site

    Metairie, Louisiana

  • Cara Therapeutics Study Site

    New Orleans, Louisiana

  • Cara Therapeutics Study Site

    Rockville, Maryland

  • Cara Therapeutics Study Site

    Brighton, Massachusetts

  • Cara Therapeutics Study Site

    Auburn Hills, Michigan

  • Cara Therapeutics Study Site

    Clinton Township, Michigan

  • Cara Therapeutics Study Site

    Detroit, Michigan

  • Cara Therapeutics Study Site

    Waterford, Michigan

  • Cara Therapeutics Study Site

    Hackensack, New Jersey

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.